BioMarin Pharmaceutical (NASDAQ: BMRN) announced Friday August 21, 2026 a definitive agreement to acquire Dutch biotech Alesta Therapeutics to gain Alesta's lead clinical-stage asset ALE1. Financial terms of the transaction were not publicly disclosed. Alesta's ALE1 program is in clinical development; the specific mechanism and indication have not been fully disclosed in initial press coverage, and additional details are expected in the deal filing documents. The acquisition adds to BioMarin's rare-disease portfolio alongside VOXZOGO (vosoritide, C-type natriuretic peptide analog administered as daily subcutaneous injection for achondroplasia in pediatric patients; delivered Q2 2026 revenue of $253 million +14% YoY and is on track for $1+ billion annual sales as BioMarin's first blockbuster franchise), the newly-integrated Amicus Therapeutics assets (GALAFOLD migalastat oral chaperone for Fabry disease, POMBILITI + OPFOLDA cipaglucosidase alfa plus miglustat for late-onset Pompe disease), and the broader enzyme-replacement franchise (VIMIZIM, Naglazyme, Aldurazyme, Palynziq). The Alesta acquisition continues BioMarin's pattern of rare-disease portfolio expansion following the Amicus integration completed earlier in 2026 that added roughly $220 million in expected non-GAAP cost synergies by 2028 and non-GAAP diluted EPS accretion beginning 2027. BioMarin's strategy of building a diversified rare-disease commercial franchise across peptide analogs (Voxzogo), oral small-molecule chaperones (GALAFOLD), enzyme replacements (Palynziq, VIMIZIM, Naglazyme, Aldurazyme), and now Alesta's ALE1 program continues to differentiate the company from single-franchise rare-disease competitors.
Samsung Biologics' all-cash tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share (CHF 1.46 billion / $1.8 billion, representing a 40% premium to the undisturbed share price of CHF 31.65) continues to progress. The formal tender offer prospectus is expected to be published by end of August 2026 and will remain open for a minimum of twenty trading days on the SIX Swiss Exchange following a ten trading-day cooling-off period under Swiss takeover law. PolyPeptide's largest individual shareholder Draupnir Holding B.V. (owning approximately 55.65% of shares outstanding) has committed to tender all of its shares into the offer. PolyPeptide's independent Board of Directors unanimously recommends that shareholders accept Samsung Biologics' offer. The transaction would substantially expand Samsung Biologics' peptide CDMO manufacturing footprint beyond its existing antibody and antibody-drug conjugate focus, positioning the combined entity to address the rapidly growing peptide therapeutics demand particularly in obesity and diabetes GLP-1 therapies (Novo Nordisk Wegovy and Ozempic, Eli Lilly Zepbound and Mounjaro), amylin analogs (cagrilintide), and next-generation combination peptide drugs. PolyPeptide operates commercial-scale peptide API manufacturing across the US, Europe, and India. Closing is expected towards the end of 2026 subject to a minimum acceptance threshold of 66⅔% and applicable regulatory approvals.
Zymeworks (NASDAQ: ZYME) announced Monday June 29, 2026 a definitive agreement to acquire Theravance Biopharma (NASDAQ: TBPH) for $17.00 per share in cash, an equity value of approximately $929 million plus a contingent value right (CVR) entitling Theravance shareholders to 80% of net proceeds from any future license, divestiture, or monetization of ampreloxetine (the late-stage program that posted topline results from the Phase 3 CYPRESS study on March 3, 2026, prompting the buyout window). The $17.00 price represents a 22% premium to Theravance's March 3 closing price and a 10% premium to the volume-weighted average price since that date. Financing comes from a $350 million non-recourse note secured by the US YUPELRI profit share from OMERS Life Sciences, plus Theravance's expected $360 million net cash balance at closing. The strategic anchor is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist for COPD that competes against GSK's Trelegy, AstraZeneca's Bevespi, and Boehringer Ingelheim's Spiriva Respimat. The transaction is expected to close in H2 2026 subject to Theravance shareholder approval and regulatory clearances. Industry context: the deal sits inside a late-June biotech consolidation wave that also produced AbbVie's $10.9B Apogee Therapeutics acquisition (June 22, anti-IL-13 zumilokibart) and Sangamo's Chapter 11 with Lilly's $50M stalking-horse bid on capsid, zinc finger, MINT, and ST-506 prion-disease assets (June 23).
Pfizer's ADA Phase 2b readout for berobenatide (15.9% weight loss at 32 weeks, no plateau, monthly dosing via a 0.5 mL low-volume injection) validates the $4.9 billion Metsera acquisition that closed earlier this year. The company now plans more than 20 obesity-related trials in 2026, including 10 Phase 3 studies. Monthly dosing positions berobenatide against once-weekly incumbents on the adherence axis, the same logic behind Amgen's MariTide and Ascletis's ASC30.
Hims & Hers' announced $1.15 billion acquisition of Eucalyptus continues to be a major catalyst for the company alongside Friday's JPMorgan Overweight upgrade. Eucalyptus brings Australia and Japan exposure, with management targeting more than $1 billion in annual international revenue within three years. Combined with the recent Eli Lilly LillyDirect partnership (Foundayo, Zepbound, KwikPen) and the FDA peptide reclassification framework, Hims now has three strategic catalysts reshaping its 2026 trajectory.